# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001628280-24-007205
Filing Date
2024-02-27
Accepted
2024-02-27 16:07:19
Documents
106
Period of Report
2023-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | bcrx-20231231.htm iXBRL | 10-K | 2174869
2 | EX-21 | exhibit21-subsidiaries1.htm | EX-21 | 8156
3 | EX-23 | exhibit23-202310xkxdraftco.htm | EX-23 | 6689
4 | EX-31.1 | bcrx-20231231xex311.htm | EX-31.1 | 9749
5 | EX-31.2 | bcrx-20231231xex312.htm | EX-31.2 | 9746
6 | EX-32.1 | bcrx-20231231xex321.htm | EX-32.1 | 6019
7 | EX-32.2 | bcrx-20231231xex322.htm | EX-32.2 | 5515
8 | EX-97 | exhibit97-nasdaqcompliantc.htm | EX-97 | 10449
14 | GRAPHIC | bcrx-20231231_g1.jpg | GRAPHIC | 106862
| Complete submission text file | 0001628280-24-007205.txt |  | 11449132

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
9 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | bcrx-20231231.xsd | EX-101.SCH | 81669
10 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | bcrx-20231231_cal.xml | EX-101.CAL | 96910
11 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | bcrx-20231231_def.xml | EX-101.DEF | 371075
12 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | bcrx-20231231_lab.xml | EX-101.LAB | 994178
13 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | bcrx-20231231_pre.xml | EX-101.PRE | 655979
108 | EXTRACTED XBRL INSTANCE DOCUMENT | bcrx-20231231_htm.xml | XML | 1669431

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-23186 | Film No.: 24686601
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)